Terms: = Head and neck cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Clinical Outcome
4 results:
1. Polymorphisms and Plasma Levels of Tissue Inhibitor of Metalloproteinase-3: Impact on Genetic Susceptibility and clinical outcome of Oral cancer.
Su CW; Huang YW; Chen MK; Su SC; Yang SF; Lin CW
Medicine (Baltimore); 2015 Nov; 94(46):e2092. PubMed ID: 26579821
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract] [Full Text] [Related]
3. The impact of tumor expression of erythropoietin receptors and erythropoietin on clinical outcome of esophageal cancer patients treated with chemoradiation.
Rades D; Golke H; Schild SE; Kilic E
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):152-9. PubMed ID: 17967510
[TBL] [Abstract] [Full Text] [Related]
4. Expression of MMP-9, timp-1, CD-34 and factor-8 as prognostic markers for squamous cell carcinoma of the tongue.
Guttman D; Stern Y; Shpitzer T; Ulanovski D; Druzd T; Feinmesser R
Oral Oncol; 2004 Sep; 40(8):798-803. PubMed ID: 15288834
[TBL] [Abstract] [Full Text] [Related]
